πŸ‡ΊπŸ‡Έ FDA
Patent

US 10457745

Anti-complement C1s antibodies

granted A61KA61K2039/54A61K2039/545

Quick answer

US patent 10457745 (Anti-complement C1s antibodies) held by Bioverativ USA Inc. expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/54, A61K2039/545, A61P, A61P13/12